CANCER FUND Impact Investments®

Two years ago, our community made its first investment in AOA Dx. Since then, AOA has advanced its AI-enabled platform aiming to improve earlier detection of ovarian cancer. On February 26 (2 PM EST/ 11 AM PST), we’ll host Co-Founder and CEO, Oriana Papin-Zoghbi for a 30-minute update covering: • Progress toward improving earlier detection • Milestones achieved since our initial investment • What comes next in bringing this innovation closer to patients If you share our passion to help ovarian cancer patients, we invite you to join us and learn more. RSVP at www.meetcancerfund.com #OvarianCancer #CancerInnovation #EarlyDetection #AIinHealthcare #ImpactInvesting

CANCER FUND Impact Investments® is pleased to announce its investment in Cellens, Inc., a Boston-based Tufts University spinout developing a novel, non-invasive diagnostic platform for bladder cancer recurrence. To date, Cancer Fund I’s has made eleven investments across eight companies, reinforcing our commitment to impactful oncology innovation. Recognizing that cancer cells “feel” different from normal, healthy cells, Cellens has developed the world’s first AI-driven mechanobiology clinical platform (BioFeel™), which analyzes urine samples to detect cellular mechanical differences associated with cancer—potentially reducing the need for invasive cystoscopy. In controlled clinical testing, the platform demonstrated 91% sensitivity and 82% specificity. “We have been highly impressed with Cellens’ platform, development progress, and potential patient impact,” said Anthony Bajoras, Managing Director of CANCER FUND. “We see strong potential to make bladder cancer monitoring less invasive and more accessible.” “We’re excited to welcome Cancer Fund I as an investor,” said Jean Pham, CEO of Cellens. “Their collaborative approach will help us advance this innovation toward improving the standard of care.” Learn more about our investment in Cellens at https://lnkd.in/gngs2yVe. Ready to fight cancer with innovation? CANCER FUND is a unique community joining together to invest in innovations with the potential to change lives. Join us or learn more at www.cancerfund.com/invest

ADVANCING PANCREATIC CANCER THERAPIES ...    From over 200 pancreatic cancer innovators in CANCER FUND’s current investment cycle, we’ve narrowed our focus to five finalists—two therapeutics and three diagnostics—each with potential to help transform outcomes for pancreatic cancer patients.   We’re honored to see some of these companies share their progress, including Peel Therapeutics, one of the therapeutic companies advancing to the next stage of our investment process.    To learn more about Peel Therapeutics, share your perspective, or express your interest in supporting cancer innovations like these with us, visit: www.cancerfund.com/peel

ACCELERATING PANCREATIC CANCER DIAGNOSTICS...   CANCER FUND’s Pancreatic Cancer Investment Cycle began with over 200 early-stage innovators. We’ve now narrowed the field to five finalists—two therapeutics and three diagnostics—each with potential to help transform outcomes for pancreatic cancer patients.   We’re honored to see some of these companies share their progress, including Amplified Sciences, Inc., one of the diagnostic innovators advancing to the “Quick-Look” screening stage of our investment process.    To learn more about Amplified Sciences, share your perspective, or express your interest in supporting cancer innovations like these with us, visit: https://lnkd.in/gteDU-Kx

This is why we backed Reglagene. RGN6024, Reglagene’s first-in-class brain-penetrant tubulin inhibitor, was recently featured on the cover of Molecular Cancer Therapeutics and highlighted by Drug Hunter for its innovation in treating glioblastoma. IND plans are underway, and the company is actively exploring partnership opportunities. Oncology scouts, BD teams, and institutional investors: now’s the time to take a serious look. #glioblastoma #braincancer #oncology #venturecapital #cancerinnovation #CANCERFUND 

AOA Dx, a CANCER FUND portfolio company, has just published peer-reviewed data showing their novel blood test can detect ovarian cancer in symptomatic women with high accuracy—outperforming traditional biomarkers. Too many cancer breakthroughs never reach patients, not because the science fails, but because they’re never fully funded. This study is more than promising, it’s a proof point that mission-aligned capital can help advance critical cancer innovations beyond the lab. We’re proud to back founders like those at AOA Dx who are redefining what’s possible in early detection—and grateful to CANCER FUND’s growing community of investors who join together to support innovations like AOA Dx. 

CANCER FUND is thrilled to be part of the @SU2C Telecast to support cancer research focused on finding cures. You won’t want to miss this, so make sure to tune in tonight, August 15th, at 8/7 Central on your favorite network. It’s one night with one goal: Beat cancer. Tune in and learn more at StandUpToCancer.org/Show. #StandUpToCancer #CANCERFUND

Is INVESTING the key to SOLVING Pancreatic Cancer? Our community investments in early-stage cancer innovators help move promising developments from research to patients. Join CANCER FUND for a look at: - The companies and cancer innovations already in our portfolio  - Why we’re investing in pancreatic cancer innovations next - Our pipeline of 200+ early-stage companies targeting pancreatic cancer  - How our unique community-driven investment model works How you can participate and help make an impact: July 24, 11:00 AM Pacific / 2:00 PM Eastern Save your spot → www.meetcancerfund.com Ask questions. Help address the problem. Own a piece of the solution. #CancerFund #ImpactInvesting #PancreaticCancer #HealthInnovation #WhatsNext

For those touched by pancreatic cancer or interested in how AI might benefit cancer patients, PanCAN and Acurion have recently announced their partnership, uniting deep clinical datasets from PanCAN’s SPARK platform with Acurion’s AI-driven diagnostics, OncoGaze™, to help personalize pancreatic cancer treatment earlier and more precisely. This is more than hope, and it’s not just research. It’s tangible progress and a move toward real solutions that could change outcomes for thousands of patients. Hat’s off to PanCAN and Acurion on this collaboration. We look forward to doing our part to help, investing in startup companies developing innovations like these targeting pancreatic and other cancers. #PancreaticCancer #CancerInnovation #PanCAN #PrecisionOncology #AIinHealthcare